We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Bioventix Plc | LSE:BVXP | London | Ordinary Share | GB00B4QVDF07 | ORD 5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 4,600.00 | 1,188 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 4,500.00 | 4,700.00 | 4,600.00 | 4,600.00 | 4,600.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 12.82M | 8.37M | 1.6071 | 28.62 | 239.63M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:12:21 | O | 35 | 4,675.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 12/4/2024 | 11:05 | UK RNS | BioVentix PLC Holding(s) in Company |
| 25/3/2024 | 14:24 | ALNC |  Bioventix ups dividend as profit rises; says headwinds temporary |
| 25/3/2024 | 07:00 | UK RNS | BioVentix PLC Interim Results |
| 29/1/2024 | 21:25 | ALNC | IN BRIEF: Bioventix CEO Harrison sells GBP2.6 million in shares |
| 29/1/2024 | 15:15 | UK RNS | BioVentix PLC Director/PDMR Shareholding |
| 07/12/2023 | 15:26 | UKREG | BioVentix PLC Result of AGM |
| 28/11/2023 | 15:26 | UKREG | BioVentix PLC Director/PDMR Shareholding |
| 16/11/2023 | 12:40 | UKREG | BioVentix PLC Holding(s) in Company |
| 10/11/2023 | 16:23 | UKREG | BioVentix PLC Posting of Annual Report and Notice of AGM |
| 07/11/2023 | 12:07 | UKREG | BioVentix PLC Holding(s) in Company |
Bioventix (BVXP) Share Charts1 Year Bioventix Chart |
|
1 Month Bioventix Chart |
Intraday Bioventix Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 16/4/2024 | 12:40 | Bioventix - Sheep Antibodies | 1,574 |
| 08/11/2016 | 13:07 | ShareSoc Supper in Brighton | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 15:12:22 | 4,675.00 | 35 | 1,636.25 | O |
| 14:43:48 | 4,550.00 | 5 | 227.50 | O |
| 14:33:29 | 4,608.00 | 50 | 2,304.00 | O |
| 13:58:53 | 4,595.00 | 250 | 11,487.50 | O |
| 13:57:28 | 4,530.00 | 13 | 588.90 | O |
| Top Posts |
|---|
Posted at 19/4/2024 09:20 by Bioventix Daily Update Bioventix Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker BVXP. The last closing price for Bioventix was 4,600p.Bioventix currently has 5,209,333 shares in issue. The market capitalisation of Bioventix is £239,629,318. Bioventix has a price to earnings ratio (PE ratio) of 28.62. This morning BVXP shares opened at 4,600p |
Posted at 25/3/2024 10:39 by melody9999 I see Cavendish have raised their price target to 5900p from 4400p in Oct 23. Will be happy to see the BVXP once again climb above the Cavendish target price! |
Posted at 21/2/2024 10:34 by stepone68 Share price starting with a '5' now. Certainly feels like it is popular at the moment. |
Posted at 12/2/2024 12:37 by maddox BVXP are in the running to develop what has been described as the 'Holy Grail' of diagnostic testing - an early stage Alzheimer's test.BBC Radio 4 Today report on new Alzheimer's treatments. Mentions that there are about 28 dementia drugs in late stage development. Whilst the current two leading drugs show efficacy the promise is of better drugs being developed. The need for an early stage diagnostic test is clear in this report. Arguably, it's equally as important to have a simple early stage test as the drugs. |
Posted at 12/2/2024 12:16 by maddox A Director's sale, if well handled, can work to enhance the share price - you sell sufficient shares to entice in a new Financial Investor - but not sell them as big a holding as they which to have. They then need to buy in the open market, creating demand and supporting the share price whilst they accumulate their desired holding.Can't say whether this is the case here but looks likely. |
Posted at 24/1/2024 09:15 by alter ego well researched 1c3479z. You're correct. I had conformation from Peter Harrison this morning. It does however, show the potential of the work being done by BVXP in this field. |
Posted at 23/1/2024 16:42 by 1c3479z not convinced- the journal article refers to an ALZpath validated immunoassay, did ALZpath also provide the antibody?in any case, should this be validated, one expects the BVXP pTau 217 might have advantages over mouse monoclonals and be commercially in high demand from various diagnostics companies eg Roche etc with a long life cycle. |
Posted at 23/1/2024 10:08 by alter ego Can't be certain but it sounds like a BVXP SMA.Sky news report today mentions " Measuring levels of a protein called p-tau217 in the blood...." "The study from Dr Nicholas Ashton at the University of Gothenburg, and colleagues, is published in the Jama Neurology journal." From BVXP Annual Report for year ended 30/6/23 "A leading blood biomarker for “A” is a phosphorylated form of tau called pTau217. A prototype assay from Gothenburg using an SMA has now been established which has performed well with frozen patient samples from a number of different cohorts." and "A novel blood-based prototype assay for neurodegeneration (N) using another Tau SMA has also been developed in Gothenburg. This work clearly supports the potential utility of this blood test and further work is ongoing in Gothenburg with further publications planned." |
Posted at 31/10/2023 09:48 by maddox If you top-up now at our shorted depressed price you'll be locking in a nice yield of c.4%.One further point the 2023 dividends of 152p looks to be no change on 2022. However, the 152p paid in 2022 included one of BVXP's regular special dividends of 26p. So, excluding this the dividends increased a very healthy 20.6%! In the last five years BVXP has paid three Special Dividends - so that 4% is probably understated albeit the corp tax increase will slow cash accumulation. |
Posted at 30/10/2023 18:10 by maddox I remember seeing an RNS from Norges Bank that had leant a tranch of shares. This explained the dip in the firm's share price - only to see the share price rebound strongly.... followed by another RNS from Norges Bank that had increased their holding. Presumably, they had picked up the shorters shares at a lower price and been paid for the privilege. |
Posted at 30/10/2023 11:38 by stepone68 Very disappointing Troponin growth. 31%, vs. 81% last year. No divi increase either, which is a first. Alzheimers might hold the key, but we rely on these 12 people being smarter than the Chinese. Share price stagnant for the last 5 years. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
